Scopus
Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes
Archives of Gynecology and Obstetrics · Eylül 2013
Makale Bilgileri
DergiArchives of Gynecology and Obstetrics
Yayın TarihiEylül 2013
Cilt / Sayfa288 · 691-695
Scopus ID2-s2.0-84882592008
Özet
Purpose: This study aims to determine whether a low dose of the gonadotropin releasing hormone antagonist, cetrorelix, prevents a premature luteinizing hormone (LH) surge and affects in vitro fertilization (IVF) outcomes compared to the standard dose of 0.25 mg/day. Methods: In this study, 45 IVF/intracytoplasmic sperm injection patients were stimulated with recombinant follicle stimulation hormone from day 2 of the cycle. Cetrorelix was injected daily from day 6 of gonadotropin administration. Twenty-two patients received cetrorelix at a dose of 0.25 mg/day, whereas 23 participants received half dose. Results: The mean consumption of gonadotropins was significantly higher in patients receiving 0.25 mg/day of cetrorelix (2,213 vs. 1,350 U; p = 0.046). The clinical pregnancy rates were similar in both groups (31.8 vs. 47.8 %; p = 0.273). Premature LH surge was detected in 9.1 % of the patients receiving cetrorelix 0.25 mg/day and in 13 % of the patients receiving cetrorelix 0.125 mg/day (p > 0.05). The difference between two groups was not statistically significant (p > 0.05). ConclusIons: Our results suggest that there is no difference between a cetrorelix dose of 0.125 or 0.25 mg/day in preventing premature LH rise during ovarian stimulation for IVF. © 2013 Springer-Verlag Berlin Heidelberg.
Yazarlar (6)
1
Özlem Seçilmiş Kerimoğlu
ORCID: 0000-0003-2208-8712
2
Cihangir Mutlu Ercan
3
Uǧur Keskin
4
Cem Korkmaz
5
Namik Kemal Duru
6
Ali Ergun
Anahtar Kelimeler
Antagonist
Cetrorelix
In vitro fertilization
LH surge
Kurumlar
Gülhane Eğitim ve Araştırma Hastanesi
Ankara Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
8
Atıf
6
Yazar
4
Anahtar Kelime